GlaxoSmithKline (GSK), a UK-listed drugs group, has committed $50m to a planned $250m fund being raised by venture capital firm Sanderling Ventures. GSK said it had committed the money to Sanderling VII at investment bank JP Morgan’s biotech conference this month, according to news provider FierceBiotech. GSK had previously committed to Index Ventures, which is…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
